Portola Pharmaceuticals, Inc. (NASDAQ: PTLA) will host a conference call and webcast on Thursday, August 15, at 8:30 a.m. Eastern Time to discuss its second quarter 2013 financial results and to provide a general business update. A press release for the second quarter of 2013 will be released prior to the opening of the markets on August 15, 2013.
Conference Call Details
To access the live conference call on August 15, 2013 at 8:30 a.m. Eastern Time via phone, please dial (800) 322-2803 from the United States and Canada or +1(617) 614-4925 internationally. The participant passcode is 69614971. Please dial in 10 minutes prior to the start of the call.
To access the live and subsequently archived webcast of the conference call, go to the Investor Relations section of the company’s website at http://investors.portola.com. Please connect to the website at least 15 minutes prior to the call to allow for any software download that may be necessary.About Portola Pharmaceuticals Portola is a biopharmaceutical company focused on the development and commercialization of novel therapeutics in the areas of thrombosis (blood clots), other hematologic (blood) disorders and inflammation for patients who currently have limited or no approved treatment options. Portola’s lead compound, betrixaban, is an investigational, novel, oral once-daily inhibitor of Factor Xa in Phase 3 development for extended-duration prophylaxis (preventive treatment) of a form of thrombosis known as venous thromboembolism (VTE) in acute medically ill patients. Currently, there is no anticoagulant approved for extended-duration VTE prophylaxis in this population. Portola’s second lead development candidate, andexanet alfa (proposed International Nonproprietary Name), is a recombinant protein designed to reverse the anticoagulant activity in patients treated with a Factor Xa inhibitor who suffer an uncontrolled bleeding episode or require emergency surgery. Portola has entered into collaboration agreements with Bristol-Myers Squibb Company and Pfizer Inc., with Bayer Pharma AG and Janssen Pharmaceuticals, Inc., and with Daiichi Sankyo to study andexanet alfa with Eliquis ® (apixaban), XARELTO ® (rivaroxaban) and edoxaban, respectively, in Portola’s Phase 2 studies. Portola retains full, worldwide commercial rights with respect to andexanet alfa. Portola’s third product candidate, PRT2070, is an orally available kinase inhibitor being developed for hematologic cancers and inflammatory disorders. PRT2070 inhibits spleen tyrosine kinase (Syk) and janus kinases (JAK), enzymes that regulate important signaling pathways. Portola plans to file an Investigational New Drug (IND) application and initiate a Phase 1/2 clinical study of PRT2070 in 2013 in patients with B-cell hematologic cancers who have failed or relapsed on existing marketed therapies or products in development, including patients with identified mutations. Portola’s fourth program, PRT2607 and other highly selective Syk inhibitors, is partnered with Biogen Idec Inc.